Brepocitinib, a potential treatment for uveitis, showed promising results in a Phase 2 clinical trial. The drug demonstrated positive outcomes in treating the inflammatory eye condition, offering hope for patients with uveitis. By continuing to use the site, users agree to the use of cookies for analytics, advertising, and site improvement. For more information on the use of cookies, users can refer to the site’s Cookie Policy and adjust their Cookie Settings accordingly.
Source link
Brepocitinib Demonstrates Promising Phase 2 Results in Uveitis Treatment
